Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing respiratory muscle fatigue.

Causes of Hypercapnic Respiratory Failure:

Several factors can disrupt the balance between ventilatory demand and supply, mainly by reducing the ventilatory supply. These factors are categorized into four main groups:

  • Central Nervous System Problems: Conditions that impair the central nervous system's ability to regulate respiratory drive contribute to hypercapnic respiratory failure. Overdoses of respiratory depressant drugs, such as opioids, decrease the brainstem's responsiveness to CO2. Likewise, brainstem infarctions or traumatic brain injuries can prevent the medulla, the respiratory control center, from correctly sensing and responding to changes in PaCO2. Additionally, high-level spinal cord injuries can affect the respiratory muscles' nerve supply.
  • Neuromuscular Disorders: Diseases like Guillain-Barré syndrome or multiple sclerosis weaken the respiratory muscles, severely limiting the body's ability to eliminate CO2 and contributing to ventilatory failure.
  • Chest Wall Abnormalities: Conditions restricting chest and diaphragm movement, such as severe obesity, flail chest, or kyphoscoliosis, impair normal lung expansion and adequate ventilation, drastically reducing the ventilatory supply.
  • Airway and Alveoli Abnormalities: Conditions like COPD, asthma, and cystic fibrosis may lead to airway obstruction and alveolar air trapping, increasing the work of breathing and compromising CO2 elimination efficiency, resulting in hypercapnia.
  • Diabetic Ketoacidosis (DKA) is a severe complication of diabetes. It occurs when the body breaks down fats too quickly due to a lack of insulin, producing acidic ketones. This process can make the blood too acidic, a condition known as metabolic acidosis. To counteract the acidosis, the body begins to breathe rapidly and deeply, a symptom called Kussmaul respirations. However, if the body is exhausted or has an underlying lung condition, this compensatory mechanism may fail, resulting in carbon dioxide retention (hypercapnia). This buildup of carbon dioxide can result in hypercapnic respiratory failure, causing severe respiratory distress and requiring urgent medical attention.

Monitoring and Management:

Close monitoring of respiratory symptoms is essential for individuals at risk of hypercapnic respiratory failure. An increased breathing difficulty or a noticeable change in carbon dioxide levels requires immediate medical attention. Prompt management measures are crucial to prevent severe complications and ensure adequate oxygenation and CO2 elimination.

Management strategies typically aim to treat the underlying cause, enhance ventilation, and provide mechanical ventilatory support when necessary. A comprehensive, multidisciplinary approach involving respiratory therapists, neurologists, and pulmonologists is vital to meet the complex needs of patients with this challenging respiratory condition.

From Chapter 3:

article

Now Playing

3.13 : Acute Respiratory Failure-III

Lower Respiratory Tract Infections

68 Views

article

3.1 : Pneumonia I: Introduction

Lower Respiratory Tract Infections

93 Views

article

3.2 : Pneumonia II: Pathophysiology

Lower Respiratory Tract Infections

79 Views

article

3.3 : Pneumonia III: Complications and Assessment

Lower Respiratory Tract Infections

53 Views

article

3.4 : Pneumonia IV: Management

Lower Respiratory Tract Infections

120 Views

article

3.5 : Pneumonia V: Nursing management and Prevention

Lower Respiratory Tract Infections

934 Views

article

3.6 : Pulmonary Tuberculosis I

Lower Respiratory Tract Infections

72 Views

article

3.7 : Pulmonary Tuberculosis II

Lower Respiratory Tract Infections

73 Views

article

3.8 : Pulmonary Tuberculosis III

Lower Respiratory Tract Infections

109 Views

article

3.9 : Pulmonary Tuberculosis IV

Lower Respiratory Tract Infections

58 Views

article

3.10 : Pulmonary Tuberculosis V

Lower Respiratory Tract Infections

42 Views

article

3.11 : Acute Respiratory Failure-I

Lower Respiratory Tract Infections

75 Views

article

3.12 : Acute Respiratory Failure-II

Lower Respiratory Tract Infections

61 Views

article

3.14 : Acute Respiratory Failure-IV

Lower Respiratory Tract Infections

52 Views

article

3.15 : Acute Respiratory Failure-V

Lower Respiratory Tract Infections

40 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved